73368-41-9

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 4-amino-3-methoxybenzoate is used as a local anesthetic agent for its ability to provide temporary pain relief. It is particularly effective in over-the-counter products such as sunburn relief creams, toothache gels, and other topical pain relief medications, where it helps to alleviate discomfort and reduce inflammation.
Used in Cosmetic Industry:
In the cosmetic industry, Ethyl 4-amino-3-methoxybenzoate is used as a skin-numbing agent in products that may cause irritation or discomfort during application, such as hair removal creams or waxing strips. Its anesthetic properties help to minimize the sensation of pain and provide a more comfortable user experience.
Used in Dental Industry:
Ethyl 4-amino-3-methoxybenzoate is also utilized in the dental industry for its numbing effects. It is often incorporated into gels and creams that are applied to the gums and teeth to reduce pain and sensitivity during dental procedures, such as tooth extractions or root canals.
Used in Veterinary Medicine:
In veterinary medicine, Ethyl 4-amino-3-methoxybenzoate serves as a local anesthetic for animals, providing pain relief during minor surgical procedures or wound treatment. Its use in this context helps to ensure the comfort and well-being of animals undergoing medical care.

Upstream product

• 10259-23-1 Ethyl 3-methoxy-4-nitrobenzoate 
• 64-17-5 ethanol 
• 2486-69-3 3-methoxy-4-aminobenzoic acid 
• 5081-36-7 3-methoxy-4-nitrobenzoic acid 
• 38512-82-2 3-methoxy-4-nitrotoluene 
• 700-38-9 2-nitro-5-methylphenol 

Downstream Products

• 755039-56-6 (R)-4-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzoic acid 
• 1234480-80-8 4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-2-yl)amino)-3-methoxybenzoic acid 
• 1606132-23-3 4-(2-aminoacetylamino)-3-methoxybenzoic acid ethyl ester hydrochloride 
• 1569084-00-9 ethyl 4-(diethylamino)-3-methoxybenzoate 
• 1569079-17-9 C₂₄H₂₈N₄O₃S 
• 1569084-03-2 C₁₄H₂₂N₄O₃ 
• 1569084-02-1 C₁₆H₂₄N₂O₄ 
• 1569084-01-0 4-(diethylamino)-3-methoxybenzoic acid 
• 1190854-43-3 [2-chloro-6-methoxy-4-(methoxymethyl)phenyl]boronic acid 

Relevant academic research and scientific papers

COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS

Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

ASYMMETRIC SYNTHESIS OF A SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDE

The present invention provides an improved method for the large scale production of the compound 4-{[(2R,3S,4R,5S)-3-(3-chloro-2-fluoro-phenyl)-4-(4-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic a

Substituted benzamides with activity towards EP4 receptors

The present invention belongs to the field of EP4 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP4 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP4 receptor as well as to pharmaceutical compositions comprising them.

SUBSTITUTED BENZAMIDES WITH ACTIVITY TOWARDS EP4 RECEPTORS

The present invention belongs to the field of EP4 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP4 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP4 receptor as well as to pharmaceutical compositions comprising them.

PYRAZOLOTHIAZOLE COMPOUND

A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism wherein X is a nitrogen atom or CH; R1 is -A11-A12; A11 is a single bond or a C1-6 alkylene group; A12 is a hydrogen atom, a C1-6 alkyl group or a C3-6 cycloalkyl group, etc.; R2 is -A21-A22; A21 is a single bond or a C1-6 alkylene group; A22 is a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a non-aromatic heterocyclic group, or a heteroaryl group, etc.; R3 is a C 1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C3-6 cycloalkoxy C1-6 alkyl group, di-C1-6 alkyl amino group, a halogen atom, a cyano group, a formyl group, or a carboxyl group, etc; R4 is a hydrogen atom or a C1-6 alkoxy group; R5 is a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group; R6 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylthio group, or a C1-6 alkyl sulfinyl group etc.; and R7 is a C1-6 alkyl group, a C1-6 alkoxy group, or a C1-6 alkylthio group

Synthesis of symmetric diester-functionalised Troeger's base analogues

The yields of ester-functionalised Troeger's base analogues are dramatically improved by incorporating an electron-donating group on the aromatic ring and/or enhancing solubil- ity of the aniline unit. In addition to 2,8-diester compounds, 1,7-, 3,9- and 4,10-diester-functionalised Troeger's base analogues have been prepared for the first time.

3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUNDS

A compound represented by the following formula (I), or salt thereof exhibits excellent CRF receptor antagonism, and sufficient pharmacological activity, safety and pharmacokinetic properties as a drug. wherein R1 represents the formula -A11-A12; R2 represents tetrahydrofurylmethyl, tetrahydropyranylmethyl or tetrahydropyranyl; A11 represents a single bond, methylene or 1,2-ethylene; A12 represents C1-6 alkyl, C3-6 cycloalkyl or C3-6 cycloalkyl having methyl; R3 represents methoxy, cyano, cyclobutyloxymethyl, methoxymethyl or ethoxymethyl; and R4 represents methoxy or chlorine.

Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains

Novel diarylpyrimidines (DAPY), which represent next generation of non-nucleoside reverse transcriptase inhibitors (NNRTIs), were synthesized and their activities against human immunodeficiency virus type I (HIV-1) assessed. Modulations at positions 2 and

Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging

The present invention provides aromatic amine substituted metal chelating compounds, chelates and chelate-targeting moiety conjugates formed from the chelating compounds, and methods for making and using these compounds. Metals capable of being chelated by the chelating compounds include radionuclides, such as 99mTc and 186188Re.

Antibody-catalyzed decarboxylative oxidation of vanillylmandelic acid

The most important industrial process for the synthesis of vanillin is performed in two steps involving an electrophilic aromatic substitution of glyoxylic acid on guaiacol followed by an oxidative decarboxylation of the intermediary α-hydroxy acids formed, thereby producing not only vanillin, but also byproducts which have to be eliminated. In the present study, we took advantage of the high specificity of catalytic antibodies to improve the synthesis of vanillin. Among 11 monoclonal antibodies elicited against the quaternary ammonium hapten H3, antibody H3-12 was found to catalyze the oxidative decarboxylation of vanillylmandelic acid (VMA), the precursor of vanillin, in the presence of sodium metaperiodate. The kinetic data of the antibody-catalyzed reaction are consistent with an ordered binding mechanism. At pH 9.0, H3-12 catalyzed the transformation of VMA into vanillin with a k(cat) of 2.70 min-1, a Michaelis-Menten constant K(a) for the binary complex of 260 μM, and a K(b) for the ternary complex of 2100 μM. The catalyzed reaction was fully inhibited by a hapten analogue with a K(i) of 10 μM. The fine specificity of anti-H3 monoclonal antibodies was determined using H3-related compounds with a competitive enzyme immunoassay. Controls demonstrating that catalytic activity is actually related to antibody binding, and mechanistic studies, are also presented.